Does Pharmacogenomics Provide an Ethical Challenge to the Utilisation of Cost-Effectiveness Analysis by Public Health Systems?

Author： Adam La Caze

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.23, Iss.5, 2005-01, pp. : 445-447

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics and the Evolution of Healthcare: Is it Time for Cost-Effectiveness Analysis at the Individual Level?

By Bala M.V.

PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. : 495-498

Adis International

Access to resources Recommend Favorite

Cost–effectiveness analysis in pharmacogenomics

By Payne Katherine Shabaruddin Fatiha H

Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. : 643-646

Future Medicine

Access to resources Recommend Favorite

Intermediate organisations: a solution for `solidaristic' health systems?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 262, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

The Role of Patient Preferences in Cost-Effectiveness Analysis: A Conflict of Values?

By Brazier John E.

PharmacoEconomics, Vol. 27, Iss. 9, 2009-09 ,pp. : 705-712

Adis International

Access to resources Recommend Favorite